Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

By sjmartinez • November 3, 2022

Weitz JI, Szekanecz Z, Charles-Schoeman C, Vranic I, Sahin B, Paciga SA, Wang Z, Hyde C, Martin DA. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. RMD Open. 2022 Nov;8(2):e002571. doi: 10.1136/rmdopen-2022-002571. PMID: 36323490.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia

Daver NG, Zeidan AM, Stein AS, Zeidner JF, Maher K, Curran E, Bixby D, Chai-Ho W, Stahl M, Yee KWL, Stevens D, Ito S, Reynolds[...]

Non-Rigid Motion-Compensated MR Multitasking for Free-Breathing Low-Dose Dynamic Contrast-Enhanced MRI in the Abdomen

Ma L, Wu C, Wang L, Lee HL, Chen J, Hu Z, Xie Y, Pandol SJ, Gaddam S, Li D, Christodoulou AG. Non-Rigid Motion-Compensated MR[...]

Multifactorial causes of severe persistent hypercalcemia in an immunosuppressed woman with chronic kidney disease

Nalluri K, Goodman EL, Pasupneti T, Nunez G, Wang EC. Multifactorial causes of severe persistent hypercalcemia in an immunosuppressed woman with chronic kidney disease. JCEM[...]